Literature DB >> 12215271

Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy.

Akseli Hemminki1, Minghui Wang, Renee A Desmond, Theresa V Strong, Ronald D Alvarez, David T Curiel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12215271     DOI： 10.1089/10430340260185139

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN： 1043-0342            Impact factor:   5.695


× No keyword cloud information.
  14 in total

Review 1.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

Review 2.  Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.

Authors:  Dmitriy Zamarin; Amir A Jazaeri
Journal:  Gynecol Oncol       Date:  2016-04       Impact factor: 5.482

3.  Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.

Authors:  Otto Hemminki; Iulia Diaconu; Vincenzo Cerullo; Saila K Pesonen; Anna Kanerva; Timo Joensuu; Kalevi Kairemo; Leena Laasonen; Kaarina Partanen; Lotta Kangasniemi; Andre Lieber; Sari Pesonen; Akseli Hemminki
Journal:  Mol Ther       Date:  2012-08-07       Impact factor: 11.454

4.  Neutralized adenovirus-immune complexes can mediate effective gene transfer via an Fc receptor-dependent infection pathway.

Authors:  Philip L Leopold; Rebecca L Wendland; Theresa Vincent; Ronald G Crystal
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

5.  A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions.

Authors:  Daniel H Sterman; Adri Recio; Andrew R Haas; Anil Vachani; Sharyn I Katz; Colin T Gillespie; Guanjun Cheng; Jing Sun; Edmund Moon; Luana Pereira; Xinzhong Wang; Daniel F Heitjan; Leslie Litzky; Carl H June; Robert H Vonderheide; Richard G Carroll; Steven M Albelda
Journal:  Mol Ther       Date:  2010-01-12       Impact factor: 11.454

6.  Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy.

Authors:  Kristian Taipale; Ilkka Liikanen; Anniina Koski; Raita Heiskanen; Anna Kanerva; Otto Hemminki; Minna Oksanen; Susanna Grönberg-Vähä-Koskela; Kari Hemminki; Timo Joensuu; Akseli Hemminki
Journal:  Mol Ther       Date:  2016-04-04       Impact factor: 11.454

Review 7.  Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer.

Authors:  Rebeca Gonzalez-Pastor; Peter S Goedegebuure; David T Curiel
Journal:  Cancer Gene Ther       Date:  2020-09-19       Impact factor: 5.987

Review 8.  Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.

Authors:  Hanni Uusi-Kerttula; Sarah Hulin-Curtis; James Davies; Alan L Parker
Journal:  Viruses       Date:  2015-11-24       Impact factor: 5.048

9.  Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites.

Authors:  V A Jennings; E J Ilett; K J Scott; E J West; R Vile; H Pandha; K Harrington; A Young; G D Hall; M Coffey; P Selby; F Errington-Mais; A A Melcher
Journal:  Int J Cancer       Date:  2013-09-18       Impact factor: 7.396

10.  Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy.

Authors:  S L Hulin-Curtis; H Uusi-Kerttula; R Jones; L Hanna; J D Chester; A L Parker
Journal:  Cancer Gene Ther       Date:  2016-05-27       Impact factor: 5.987
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.